Economic outcomes in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate plus prednisone

Abstract Authors: Krishnan Ramaswamy, Stanislav Lechpammer, Jack Mardekian, Ahong Huang, Neil M Schultz, Rickard Sandin, Li Wang, Onur Baser, Daniel J George Introduction: Prostate cancer (PC) is the second leading cause of cancer death among US men and accounts for...

Transitioning from oral risperidone or paliperidone to once-monthly paliperidone palmitate: a real-world analysis among VHA patients with schizophrenia with at least one prior hospitalization

Abstract Authors: Antoine El Khoury, Charmi Patel, Ahong Huang, Li Wang, Richa Bashyal Objective: To address gaps in the literature on healthcare resource utilization (HRU) and costs among patients with schizophrenia and prior hospitalization who transition from oral...

Health outcomes among patients diagnosed with schizophrenia in the US Veterans Health Administration population who transitioned from once-monthly to once-every-3-month paliperidone palmitate: An observational retrospective analysis

Abstract Authors: Charmi Patel, Antoine El Khoury, Ahong Huang, Li Wang, Onur Baser, Kruti Joshi Introduction: There is limited literature on treatment patterns, healthcare resource utilization (HRU), and costs among patients who transition from once-monthly...